Article
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
European journal of endocrinology - 1 Nov 2012
Vroonen Laurent, Jaffrain-Rea Marie-Lise, Petrossians Patrick, Tamagno Gianluca, Chanson Philippe, Vilar Lucio, Borson-Chazot Françoise, Naves Luciana A, Brue Thierry, Gatta Blandine, Delemer Brigitte, Ciccarelli Enrica, Beck-Peccoz Paolo, Caron Philippe, Daly Adrian F, Beckers Albert
Abstract excerpt
BACKGROUND: Dopamine agonist resistance in prolactinoma is an infrequent phenomenon. Doses of cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling prolactin (PRL) secretion and reducing tumor size in prolactinomas. The clinical presentation, management, and outcome of patients that are not well controlled by such commonly used doses of CAB-resistant patients are poorly understood. DESIGN...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.